The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Tiotropium Bromide in Cystic Fibrosis
Study DrugTiotropium Bromide
Type of Study DrugBronchodilator
Study TitleA Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 Mcg and 5 Mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis
Study Phase2
Study SponsorBoehringer Ingelheim Pharmaceuticals

Link on (link is external) (link is external)

Participating ECFS-CTN sitesStudy Closed
AgeAdults and Pediatrics

Study Results

Study Results